Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

Generation Bio is shedding 90% of its workforce after the biotech acknowledged that it’s unlikely to find the cash to take ...

Using its hub-and-spoke business model, PureTech is launching a new company to develop deupirfenidone (LYT-100), its ...

After the Department of Health and Human Services canceled about $500 million in funding for mR | After HHS abruptly canceled ...

The director of the National Institutes of Health (NIH) has said the federal government’s discontinuation of mRNA vaccine ...

The company said its CGM+ system can deliver accurate readings across a 15-day lifespan, while also employing fewer ...

Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting in its tail—the therapeutic-resistance-focused biotech is laying off 20 | ...

More bad news has come down for Biohaven’s small molecule troriluzole. | More bad news has come down for Biohaven’s small molecule troriluzole. After the FDA decided to convene an advisory committee ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Activist investor Engine Capital is lobbying for big changes at Avantor, urging the life science toolmaker to either cut costs and reshape its management or sell itself outright. | The move comes as ...

Vaxart is actively seeking more information about why it was told to stop work under a federally funded COVID-19 vaccine ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...